Budget impact of Envudeucitinib
5 evidence topics · 26 sources
Summary: price and economic analyses of envudeucitinib
Envudeucitinib is “an investigational drug, not reviewed or approved by any regulatory agency”, and Alumis plans to submit its New Drug Application to the FDA in the fourth quarter of 2026. The report records no price for envudeucitinib, no budget impact model, and no published economic analysis that includes it. In its annual report, Alumis states that its projections of the number of people with the diseases it aims to address, and of those who could benefit from its product candidates, “are based on our beliefs and estimates” and that pricing of competitive products may limit the amount it will be able to charge for its product candidates, if approved.
Summary: comparator prices by source and date
Package prices are given as each file lists them, in U.S. dollars.
- Deucravacitinib (Sotyktu): WAC price 7135.55 in the Texas DSHS 2026 annual WAC report; for SOTYKTU 6MG TAB, package of 30, an FSS price of 6088.27 and a Big Four price of 4815.81 from 01/01/2026 in the Department of Veterans Affairs file. Bristol Myers Squibb states that beginning January 2026, eligible cash-pay U.S. patients can buy Sotyktu through BMS Patient Connect at more than 80% less than the current list price.
- Icotrokinra (ICOTYDE): 200mg tablet, package size 30, WAC at introduction 8285.0000 on 2026-03-18 (California HCAI new prescription drugs file).
- Apremilast (Otezla): 5589.89 for the 30mg 60 pack and for the 75 mg extended-release 30 pack, effective 01/07/2026 (California HCAI WAC increase file). The Medicare negotiated price for Otezla and Otezla XR is $1,650 for a 30-day supply in CY 2027, against a CY 2024 list price of $4,722 for a 30-day supply, a 65% discount.
- Injectable biologics: SKYRIZI 150 mg pen 23838.42 (effective 01/02/2026), COSENTYX 300 mg pen 8492.03 (effective 01/07/2026), and SILIQ 210 mg box of 2 syringes 6928.92 (effective 05/11/2026) in the California HCAI WAC increase file; TREMFYA 14566.44, STELARA 29151.48, Otulfi 45 mg 1809.79, and SELARSDI 45 mg 2088.21 in the Texas DSHS 2026 annual WAC report.
- Cosentyx and Cimzia are among the drugs selected for the third cycle of Medicare negotiation, with any negotiated prices effective beginning in 2028.
Summary: eligible population and U.S. economic burden
- Prevalence: approximately 3.0% of U.S. adults aged 18 years and older reported a history of psoriasis, approximately 7.9 million adults in 2023 (National Health Interview Survey, Smith et al.); psoriasis prevalence among U.S. adults 20 years or older was 3.0%, approximately 7.55 million adults based on 2020 census data (NHANES, Armstrong et al.). The manufacturer of icotrokinra states in its California filing that over 8 million people in the US are living with psoriasis and that exact information for the indicated population is not available in the public domain.
- Moderate-to-severe fraction: 21.5% of participants reported moderate to severe psoriasis (3 or more palms of body surface area) (NHANES, Armstrong et al.); 18.2% reported moderate or severe disease (Helmick et al.); 16.63% of those with a physician diagnosis had disease covering 3% or greater body surface area, with an estimated 1.4 million people age 20 to 59 with moderate to severe disease (Kurd and Gelfand).
- Insured and untreated: an estimated 1.7 million insured U.S. patients had moderate to severe psoriasis, of whom 1 million (59%) were not treated for their condition in the preceding year; in the 5-year analysis window, 546,814 of 1,700,266 (32.2%) were diagnosed but not treated, and 40.9% were receiving therapy in the 12 months up to September 2012 (health-plan claims, Armstrong et al.).
- Economic burden: the annual U.S. cost of psoriasis amounted to approximately $112 billion in 2013 in a systematic review of 22 studies (Brezinski et al.), and the total burden was estimated at $35.2 billion in another 2013 estimate (Vanderpuye-Orgle et al.). Adults aged 18 to 64 with moderate-to-severe psoriasis had annual total health care costs of $22,713 per patient against $4,993 for matched controls, in 2012 U.S. dollars (Feldman et al.). All-cause health care costs per patient per year were $21,481 for moderate-to-severe disease and $29,832 for patients on biologics, in 2014 US dollars (Al Sawah et al.). Among patients initiating biologics, the average annual treatment cost, using commercial estimates of net prices, rose from $21,236 in 2007 to $47,125 in 2021 (Rome et al.).
Summary: ICER assessments and published budget impact analyses of comparators
- ICER 2016 report: the candidate population was adults with moderate-to-severe plaque psoriasis taking a biologic agent for the first time, approximately 36,750 incident cases per year. The budget impact threshold for 2015-16 was $904 million per year for new drugs; the total potential budgetary impact over five years was approximately $1.2 billion for brodalumab ($239.8 million per year) and approximately $1.3 billion for ixekizumab ($266 million per year).
- ICER 2018 report: the same candidate population gave an average of 29,342 incident cases of moderate-severe plaque psoriasis per year, approximately 146,710 over five years. At all prices except the price to reach $50,000 per QALY, the annual potential budgetary impact for the entire eligible population exceeded the annual threshold of $915 million; the additional per-patient cost averaged approximately $58,900 at WAC and approximately $37,200 with the assumed discount. At a $50K/QALY threshold no targeted drug offered good value, and discounts of 38% to 71% were required to reach $100,000 per QALY.
- Carrico et al.: in a health plan of 1 million members with an estimated 1048 patients receiving biologics or apremilast for psoriasis, adding tildrakizumab reduced total health plan cost by a cumulative $964,763 over 5 years, with per member per month reductions of $0.03 or less.
- Feldman et al.: in a hypothetical commercial health plan of two million members with 7,038 patients estimated to be eligible, brodalumab use of 3% to 30% reduced the total annual pharmacy cost by $3,698,129 to $36,981,290.
- Park et al.: the cost per response of deucravacitinib was lower than that of apremilast at 16 weeks (difference -$3796) and 24 weeks (difference -$12,784).
Summary: market statements by Alumis
In its corporate presentation, Alumis describes psoriasis as a “Large marketplace with modest treatment penetration” and states that the uptake of Icotyde is largely additive and that historical market share trends show a multi-winner market. The presentation reports that 84% of patients and 73% of dermatologists believe there is a need for better psoriasis therapies.